Скачать с ютуб Pharma Sector - Understanding Entire Value Chain в хорошем качестве

Pharma Sector - Understanding Entire Value Chain

In this comprehensive video, we delve into the intricate details of the entire value chain of the Pharma sector. From research and development to production, marketing, and distribution, we explore every stage in the process of bringing pharmaceutical products to the market. Gain a deep understanding of the complex network involved in the Pharma industry as we dissect the supply chain, regulatory environment, and various stakeholders' roles. Whether you are an industry professional, investor, or simply curious about the workings of this vital sector, this video provides invaluable insights 00:00 Introduction 01:15 Global Pharma Market (USD B) 03:57 Global Pharma Market – Innovators vs Generic (US$ billion) 06:38 PHARMA VALUE CHAIN 09:19 R&D 14:40 Estimated Market Spending vs Outsourced Spend 2017 17:56 R&D Outsourcing From India 25:41 ANDA approvals from US FDA 27:27 R&D as a % of Sales 28:13 Manufacturing 33:10 CDMO, CRO & CRAMS 35:18 CRAMS INDUSTRY 37:20 Indian Player in CRAMS Industry 40:36 Overview of API industry in India 44:16 Indian Players’ US Business 45:44 Indian Branded 46:55 Indian Pharma Value Chain (%MRP Build up) 47:37 IPM-Acute vs Chronic 48:46 IPM by Therapy 50:50 Key Players in the OTC market in India 53:14 IPM - Average NLEM contribution in IPM sales 53:57 Biggest Pharma Complete Fundamental Stock Analysis Tool - Stock-o-meter: https://investyadnya.in/stock-o-meter Research Based Ready-made Model Portfolios: https://investyadnya.in/model-portfolios Comprehensive Mutual Fund Reviews: https://investyadnya.in/fund-o-meter Yadnya Books and eBooks now available: On Amazon - https://amzn.to/2XKtlks On our website - https://investyadnya.in/books Find us on Social Media and stay connected: Blog - https://blog.investyadnya.in Telegram - http://t.me/InvestYadnya Facebook Page -   / investyadnya   Facebook Group - https://goo.gl/y57Qcr Twitter -   / investyadnya   LinkedIn -   / investyadnya   #PharmaSectorExplained #ValueChainInPharma #PharmaceuticalProducts #IndustryInsights #PharmaMarketTrends #ExplorePharmaIndustry #PharmaceuticalSupplyChain #RegulatoryEnvironment LEGAL DISCLAIMER: Use of this information is at the user's own risk. The Company and its directors, associates and employees will not be liable for any loss or liability incurred to the user due to investments made or decisions taken based on the information provided herein. The investment discussed or views expressed herein may not be suitable for all investors. The users should rely on their own research and analysis and should consult their investment advisors to determine the merit, risks and suitability of recommendation. Past performance is not a guarantee for future performance or future results. Information herein is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The images used may be copyright of the company or third party. As a condition to using the services, the user agrees to the terms of use of the website and the services. DISCLOSURES UNDER SEBI (RESEARCH ANALYST) REGULATIONS, 2014: Yadnya Academy Pvt. Ltd. (InvestYadnya) is registered with SEBI under SEBI (Research Analyst) Regulations, 2014 with registration no. INH000008349. Disclosure with regard to ownership and material conflicts of interest 1. Neither Research Analyst nor the entity nor his associates or relatives have any financial interest in the subject Company; 2. Neither Research Analyst nor the entity nor its associates or relatives have actual / beneficial ownership of one per cent or more securities of the subject Company, at the end of the month immediately preceding the date of publication of the research report or date of public appearance; 3. Neither Research Analyst nor the entity nor its associates or his relatives have any other material conflict of interest at the time of publication of the research report or at the time of public appearance. Disclosure with regard to receipt of Compensation 1. The Research Entity and its associates have not received compensation from the subject company in the past twelve months. 2. The subject company is not or was not a client during the twelve months preceding the date of recommendation.